Latest

psychopharmacology

This shows a scale, a pill and mushrooms.

·March 18, 2026·9 min read

Psychedelics Match, But Don’t Beat, Traditional Antidepressants

New research reveals that the perceived advantage of psychedelics over antidepressants disappears when the "knowledge of treatment" factor is equalized.

This shows a head surrounded by mushrooms.

Featured Neuroscience Psychology

·March 6, 2026·6 min read

Healing Without the Hallucinations: The Next Generation of Psilocybin Therapy

Scientists have synthesized a new compound that delivers the benefits of magic mushrooms without the mind-altering side effects.

Featured Neuroscience Psychology

·March 4, 2026·8 min read

Psychedelics Remodel Myelin to Heal PTSD

New research reveals that psychedelics don't just rewire the brain—they physically repair the "neural insulation" needed to sustain long-term PTSD recovery.

Neuroscience

·February 28, 2026·7 min read

Ketamine Revolution: Study Redefines Depression Treatment

Pioneering research into ketamine has moved depression treatment away from slow-acting serotonin drugs toward rapid-acting glutamate therapy.

Featured Neuroscience Psychology

·February 23, 2026·5 min read

Moving Beyond Dopamine to Treat Schizophrenia

Dopamine isn't the whole story. A massive new review outlines the next generation of schizophrenia therapies that target the immune system, the gut, and cognitive receptors.

Featured Neuroscience Psychology

·February 22, 2026·7 min read

Could an “Exercise Pill” Help Treat Depression?

Exercise is medicine, but what if you can't take the dose? Scientists explore "exercise mimetics"—pills that trick your brain into thinking you've just finished a workout.

This shows a head with psychedelic images surrounding it, implying DMT's affect on resolving depression.

Featured Neuroscience Psychology

·February 17, 2026·9 min read

Single DMT Dose Provides Lasting Relief from Depression

A 25-minute "trip" for six months of relief? Researchers have found that the ayahuasca compound DMT provides a rapid, durable shield against depression.

Featured Neuroscience Psychology

·February 13, 2026·8 min read

Antidepressants May Safeguard Against Preterm Birth Risks

Does treating depression with antidepressants during pregnancy harm the baby? A massive new study reveals that while SSRIs increase gestational diabetes risk, they also protect against preterm birth.

Neuroscience

·December 10, 2025·7 min read

Anti-Inflammatory Treatments Show Promise for Depression

A new analysis shows that anti-inflammatory medications may help reduce symptoms for a subset of people with depression who also have chronic, low-grade inflammation. By reviewing randomized controlled trials that specifically enrolled individuals with elevated inflammatory markers, researchers found that anti-inflammatory treatments significantly reduced both overall depressive symptoms and anhedonia.

Featured Neuroscience Psychology

·November 28, 2025·7 min read

CBD Can Reduce Aggression in Dogs

A massive multi-year analysis of tens of thousands of dogs reveals that CBD use is becoming increasingly common among aging companion animals. While dogs given CBD initially showed higher aggression, their aggression decreased below average levels with long-term use.

This shows the outline of a head in psychedelic colors.

Featured Neuroscience Psychology

·November 24, 2025·4 min read

Psychedelic ‘Ego Death’ Tied to a Collapse in Alpha Brain Waves

A new study using DMT as a scientific tool reveals how psychedelics alter the brain’s alpha-wave dynamics and weaken our sense of self. The researchers found that DMT pushes the brain away from its usual “critical” balance between chaos and order, a state believed to be essential for coherent self-awareness over time.

Featured Neuroscience Psychology

·November 6, 2025·6 min read

New Drug Exposes Hidden Subtypes of Psychosis

A new study examining real-world hospital data reveals early indicators of who is most likely to benefit from Cobenfy, the first new schizophrenia drug mechanism approved in 50 years. Patients with strong negative symptoms responded best to the xanomeline–trospium combination, showing notable improvements in social behavior and mood.